Close Menu

NEW YORK (360Dx) – Following on a series of distribution agreements for markets around the world, Israeli molecular diagnostics firm MicroMedic is aiming to expand into the US with its liquid biopsy assay for detecting early-stage urothelial carcinoma.

According to MicroMedic, its CellDetect assay diagnoses bladder cancer in about twenty minutes using a unique plant-based dye that distinguishes between malignant and benign cells.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.